Okyo Pharma Ltd. (OKYO)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN 
OKYO Pharma's neuropathic corneal pain study greenlit by FDA - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week confirmed it is set to launch a Phase 2b/3 clinical trial for neuropathic corneal pain, following a productive Type C meeting with the US Food and Drug Administration (FDA). In a conversation with Proactive, chief executive Robert Dempsey said the regulatory meeting provided "a clear line of sight" for advancing the programme, which targets a condition he described as severely debilitating and significantly underserved.
OKYO Pharma to present urcosimod Phase 2 results at ASCRS 2026 annual meeting
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that an abstract on its lead candidate, urcosimod, has been accepted for presentation at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The abstract, titled “Evaluation of Urcosimod in Neuropathic Corneal Pain: Efficacy and Safety Results from a Proof-of-Concept Pilot Phase 2 Study”, will be presented in the Ocular Surface Disease II session on April 11, 2026, in Washington, DC.
OKYO Pharma reports positive FDA feedback on planned neuropathic corneal pain trial
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has received positive feedback from the US Food and Drug Administration (FDA) following a Type C meeting on the design of its planned Phase 2b/3 clinical trial of its investigational therapeutic urcosimod for the treatment of neuropathic corneal pain (NCP). The company said the FDA agreed that the proposed primary endpoint, reduction in pain measured by the Visual Analogue Scale at Week 12, is clinically meaningful, including acknowledgment that a two-point or greater improvement on the scale represents a meaningful treatment effect.
OKYO Pharma gets FDA nod for compassionate use of eye drug in neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) said on Friday the US Food and Drug Administration has authorized a single-patient expanded access, or compassionate use, investigational new drug application for its experimental eye therapy urcosimod to treat neuropathic corneal pain. The FDA authorization allows urcosimod, at a 0.05% dose, to be used in a patient with severe neuropathic corneal pain who has limited treatment options and no FDA-approved therapies available.
OKYO Pharma names ophthalmology veteran Robert Dempsey as CEO
OKYO Pharma Ltd (NASDAQ:OKYO) has appointed ophthalmology veteran Robert Dempsey as its new CEO. The NASDAQ-listed, clinical-stage biopharmaceutical company said Dempsey takes on the CEO role with immediate effect and will also join the board as an executive director.
OKYO Pharma reports favorable outcomes from Phase 2 neuropathic corneal pain study
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing treatments for neuropathic corneal pain (NCP), said patients treated with its investigational therapy urcosimod in its recently completed Phase 2 trial showed improvements in corneal nerve structure, a potential indicator of nerve restoration. The 18-patient, randomized, double-masked, placebo-controlled trial evaluated corneal nerve health using in vivo confocal microscopy.
OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the recently announced topline data from the company's Phase 2 trial evaluating urcosimod in patients with neuropathic corneal pain. Jacob explained that neuropathic corneal pain is a severe nerve pain condition without any FDA-approved treatments, describing it as “like having a spinal cord injury in your eye.
OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapy
OKYO Pharma Ltd (NASDAQ:OKYO) announced it has secured $1.9 million in non-dilutive funding to support the development of urcosimod, its lead drug candidate for neuropathic corneal pain (NCP). NCP is a chronic, nerve-related ocular condition that currently has no US Food and Drug (FDA)-approved treatments.
OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) on Wednesday reported promising top-line results from a Phase 2 trial of its investigational drug urcosimod for neuropathic corneal pain (NCP), with 75% of patients showing greater than 80% pain reduction after 12 weeks of treatment. Patients treated with the 0.05% formulation of urcosimod saw a statistically significant reduction in pain scores compared to baseline, as measured by the Visual Analogue Scale (VAS), with an average improvement of 5.5 points versus 2.75 in the placebo group.
OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts
Shares of OKYO Pharma Ltd (NASDAQ:OKYO) have nearly doubled since the start of the year, fueled by a string of clinical and regulatory milestones that may pave the way for a transformative treatment in the underserved field of ocular pain. In a new note research report, Goldman Small Cap Research raised its price target on the stock to $8, up from $5, citing strong momentum, accelerated clinical progress, and growing interest from patients and clinicians alike in the company's lead drug candidate, urcosimod.
OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summit
OKYO Pharma Ltd (NASDAQ:OKYO) shares could see renewed attention this week as the company's chief executive, Gary Jacob, is set to present findings on its lead drug candidate at a biotech conference in Boston. Jacob will speak at the GPCRs-Targeted Drug Discovery Summit on May 22, where he'll share the latest data on urcosimod, a treatment in development for neuropathic corneal pain—a chronic eye condition that causes severe discomfort and currently has no approved therapies.
OKYO moves toward FDA talks after eye drug trial – ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the early termination of its Phase 2 trial evaluating urcosimod (formerly OK-101) for neuropathic corneal pain. The company said the 48-patient study, which began in October 2024, was initially planned to continue through the end of the year.
